RET51(C618F) has unique biochemical properties among MEN-associated RET mutants, which suggest that all of RET-activating mutations do not necessarily cause the intestinal aganglionosis by RET gene dosage reduction. This evidence concerns the gene RET and multiple endocrine neoplasia.